Evidence map›Paper›PMID 37474972›Full record

ArticleMolecular cancer2023

Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer.

Juan Xu, Tingting Shao, Mingxu Song, Yunjin Xie, Jialiang Zhou, Jiaqi Yin, Na Ding, Haozhe Zou, Yongsheng Li, Jiwei Zhang

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Juan Xu *Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou, 571199, China. xujuanbiocc@ems.hrbmu.edu.cn.
Tingting Shao *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Mingxu Song *Wuxi Oncology Institute, The Affiliated Hospital of Jiangnan University, Wuxi, 214062, China.
Yunjin XieCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Jialiang ZhouDepartment of radiation oncology, The Affiliated Hospital of Jiangnan University, Wuxi, 214062, China.
Jiaqi YinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Na DingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Haozhe ZouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Yongsheng LiKey Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou, 571199, China. liyongsheng@hainmc.edu.cn.
Jiwei ZhangThe MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Mdicine, Shanghai, 201203, China. joveus1024@gmail.com.
Harbin Medical University · CNWuxi Fourth People's Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37474972
PMCPMC10357589
OpenAlexW4384924830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.